Cargando…
A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2
The development of safe and effective vaccines to prevent SARS-CoV-2 infections remains an urgent priority worldwide. We have used a recombinant vesicular stomatitis virus (rVSV)-based prime-boost immunization strategy to develop an effective COVID-19 vaccine candidate. We have constructed VSV genom...
Autores principales: | Kim, Gyoung Nyoun, Choi, Jung-ah, Wu, Kunyu, Saeedian, Nasrin, Yang, Eunji, Park, Hayan, Woo, Sun-Je, Lim, Gippeum, Kim, Seong-Gyu, Eo, Su-Kyeong, Jeong, Hoe Won, Kim, Taewoo, Chang, Jae-Hyung, Seo, Sang Hwan, Kim, Na Hyung, Choi, Eunsil, Choo, Seungho, Lee, Sangkyun, Winterborn, Andrew, Li, Yue, Parham, Kate, Donovan, Justin M., Fenton, Brock, Dikeakos, Jimmy D., Dekaban, Gregory A., Haeryfar, S. M. Mansour, Troyer, Ryan M., Arts, Eric J., Barr, Stephen D., Song, Manki, Kang, C. Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675757/ https://www.ncbi.nlm.nih.gov/pubmed/34914812 http://dx.doi.org/10.1371/journal.ppat.1010092 |
Ejemplares similares
-
Correction: A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2
por: Kim, Gyoung Nyoun, et al.
Publicado: (2022) -
Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8(+) T cells against SARS-CoV-2 variants
por: Parham, Kate A., et al.
Publicado: (2023) -
First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses
por: Choi, Eunsil, et al.
Publicado: (2016) -
Viral Bimolecular Fluorescence Complementation: A Novel Tool to Study Intracellular Vesicular Trafficking Pathways
por: Dirk, Brennan S., et al.
Publicado: (2015) -
HIV-I Nef inhibitors: a novel class of HIV-specific immune adjuvants in support of a cure
por: Dekaban, Gregory A., et al.
Publicado: (2017)